MCID: NNL001
MIFTS: 38

Non-Langerhans-Cell Histiocytosis

Categories: Rare diseases, Immune diseases

Aliases & Classifications for Non-Langerhans-Cell Histiocytosis

MalaCards integrated aliases for Non-Langerhans-Cell Histiocytosis:

Name: Non-Langerhans-Cell Histiocytosis 12 50 14
Histiocytosis, Non-Langerhans-Cell 50 42 69

Classifications:



External Ids:

Disease Ontology 12 DOID:4330
MeSH 42 D015616
SNOMED-CT 64 127069007
UMLS 69 C0019624

Summaries for Non-Langerhans-Cell Histiocytosis

MalaCards based summary : Non-Langerhans-Cell Histiocytosis, also known as histiocytosis, non-langerhans-cell, is related to juvenile xanthogranuloma and erdheim-chester disease. An important gene associated with Non-Langerhans-Cell Histiocytosis is CD163 (CD163 Molecule), and among its related pathways/superpathways are Lysosome and LDL Oxidation in Atherogenesis. The drugs Busulfan and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, testes and bone marrow, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Non-Langerhans-Cell Histiocytosis

Diseases related to Non-Langerhans-Cell Histiocytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 95)
id Related Disease Score Top Affiliating Genes
1 juvenile xanthogranuloma 32.6 ACTC1 CD163 DES F13A1
2 erdheim-chester disease 11.5
3 histiocytosis, progressive mucinous 11.2
4 reticulohistiocytic granuloma 11.2
5 tracheo-esophageal fistula-hypospadias syndrome 10.7 ACTC1 F13A1
6 scn8a encephalopathy 10.7 ACTC1 F13A1
7 marfanoid habitus-inguinal hernia-advanced bone age syndrome 10.7 ACTC1 DES
8 esophagus leiomyosarcoma 10.7 ACTC1 DES
9 neuromuscular junction disease 10.7 DES F13A1
10 spleen angiosarcoma 10.7 ACTC1 DES
11 myoma 10.7 ACTC1 DES
12 skin lipoma 10.7 ACTC1 DES
13 cataract congenital autosomal dominant 10.7 DES F13A1
14 laryngeal neuroendocrine tumor 10.7 ACTC1 DES
15 uniparental disomy of chromosome 11 10.7 ACTC1 DES
16 myxoid leiomyosarcoma 10.7 ACTC1 DES
17 berk-tabatznik syndrome 10.7 ACTC1 DES
18 follicular infundibulum tumor 10.6 ACTC1 DES
19 punctate palmoplantar keratoderma type 2 10.6 ACTC1 DES
20 liver angiosarcoma 10.6 ACTC1 DES
21 spindle cell liposarcoma 10.6 ACTC1 DES
22 ataxia with vitamin e deficiency 10.6 NPC1 SMPD1
23 sebaceous adenoma 10.6 ACTC1 DES
24 short-rib thoracic dysplasia 12 10.6 ACTC1 DES
25 limbic encephalitis with nmda receptor antibodies 10.6 NPC1 NPC2
26 congenital enterovirus infection 10.6 NPC1 NPC2
27 mucopolysaccharidosis type 2, attenuated form 10.6 NPC1 NPC2
28 mucopolysaccharidosis type 2, severe form 10.6 NPC1 NPC2
29 pulmonary fungal infections in patients deemed at risk 10.6 NPC1 NPC2
30 bladder cancer, childhood 10.6 ACTC1 SST
31 coronary restenosis 10.6 ACTC1 DES
32 histiocytosis 10.6
33 nephrogenic adenoma of urinary bladder 10.6 ACTC1 DES
34 glomangioma 10.6 ACTC1 DES
35 urethral urothelial papilloma 10.5 CD163 CD68
36 large cell acanthoma 10.5 ACTC1 DES
37 teeth hard tissue disease 10.5 CD163 CD68
38 testicular spermatocytic seminoma 10.5 CD163 CD68
39 small intestine neuroendocrine neoplasm 10.5 CD163 DES F13A1
40 common bile duct neoplasm 10.5 CD163 CD68
41 multiple mitochondrial dysfunctions syndrome 2 10.5 ACTC1 DES
42 fibrillary astrocytoma 10.5 CD163 CD68
43 gigantism 10.5 CD68 DES
44 localized pulmonary fibrosis 10.5 ACTC1 CD68
45 aortic aneurysm 10.5 ACTC1 DES F13A1
46 secondary pulmonary hemosiderosis 10.4 ACTC1 DES F13A1
47 granular cell leiomyosarcoma 10.4 CD68 DES
48 polyneuropathy in collagen vascular disease 10.4 CD163 CD68
49 patent ductus arteriosus and bicuspid aortic valve with hand anomalies 10.4 ACTC1 DES F13A1
50 small cell neuroendocrine carcinoma 10.4 ACTC1 DES F13A1

Graphical network of the top 20 diseases related to Non-Langerhans-Cell Histiocytosis:



Diseases related to Non-Langerhans-Cell Histiocytosis

Symptoms & Phenotypes for Non-Langerhans-Cell Histiocytosis

MGI Mouse Phenotypes related to Non-Langerhans-Cell Histiocytosis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.01 ACTC1 CD163 DES F13A1 IL1RN NPC1
2 homeostasis/metabolism MP:0005376 10 ACTC1 CD163 DES F13A1 HEXA IL1RN
3 cellular MP:0005384 9.97 DES IL1RN NPC1 NPC2 PITX3 SMPD1
4 hematopoietic system MP:0005397 9.97 IL1RN NPC1 NPC2 PITX3 SMPD1 CD163
5 immune system MP:0005387 9.81 CD163 CD207 CD68 IL1RN NPC1 NPC2
6 mortality/aging MP:0010768 9.61 ACTC1 DES F13A1 HEXA IL1RN NPC1
7 respiratory system MP:0005388 9.02 F13A1 NPC1 NPC2 PITX3 SMPD1

Drugs & Therapeutics for Non-Langerhans-Cell Histiocytosis

Drugs for Non-Langerhans-Cell Histiocytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 129)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 3,Phase 2,Early Phase 1 55-98-1 2478
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
3
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
5
Hydrocortisone Approved, Vet_approved Phase 3,Phase 2 50-23-7 5754 657311
6
Methotrexate Approved Phase 3,Phase 2 1959-05-2, 59-05-2 126941
7
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
8
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
10
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
11
Miglustat Approved Phase 3,Phase 2,Phase 1 72599-27-0 51634
12
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 83-43-2 6741
13
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 50-24-8 5755
14
Asparaginase Approved Phase 3 9015-68-3
15
Pegaspargase Approved, Investigational Phase 3 130167-69-0
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
18
Butyric Acid Experimental Phase 3,Phase 2 107-92-6 264
19
Doxil Approved June 1999 Phase 3,Phase 2 31703
20
1-Deoxynojirimycin Experimental Phase 3,Phase 2 19130-96-2 1374
21 Alkylating Agents Phase 3,Phase 2
22 Anti-Bacterial Agents Phase 3,Phase 2
23 Antibiotics, Antitubercular Phase 3,Phase 2
24 Antiemetics Phase 3,Phase 2,Phase 1
25 Antifungal Agents Phase 3,Phase 2,Phase 1
26 Anti-Infective Agents Phase 3,Phase 2,Phase 1
27 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1
28 Antilymphocyte Serum Phase 3,Phase 2
29 Antimetabolites Phase 3,Phase 2
30 Antimetabolites, Antineoplastic Phase 3,Phase 2
31 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
33 Antirheumatic Agents Phase 3,Phase 2,Phase 1
34 Autonomic Agents Phase 3,Phase 2,Phase 1
35 BB 1101 Phase 3,Phase 2
36 Calcineurin Inhibitors Phase 3,Phase 2,Phase 1
37 Cortisol succinate Phase 3,Phase 2
38 Cyclosporins Phase 3,Phase 2,Phase 1
39 Dermatologic Agents Phase 3,Phase 2,Phase 1
40 Dexamethasone acetate Phase 3,Phase 2 1177-87-3
41 Etoposide phosphate Phase 3,Phase 2
42 Folic Acid Antagonists Phase 3,Phase 2
43 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
44 glucocorticoids Phase 3,Phase 2,Phase 1
45 Hormone Antagonists Phase 3,Phase 2,Phase 1
46 Hormones Phase 3,Phase 2,Phase 1
47 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
48 Hydrocortisone 17-butyrate 21-propionate Phase 3,Phase 2
49 Hydrocortisone acetate Phase 3,Phase 2
50 Hydrocortisone-17-butyrate Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 77)

id Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis Unknown status NCT00334672 Phase 3 busulfan;cyclophosphamide;cyclosporine;dexamethasone;etoposide;methotrexate;mycophenolate mofetil;therapeutic hydrocortisone
2 T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders Unknown status NCT00176826 Phase 2, Phase 3 Myeloablative conditioning regimen
3 Application of Miglustat in Patients With Niemann-Pick Type C Completed NCT01760564 Phase 3 Miglustat
4 Stem Cell Transplant for Inborn Errors of Metabolism Completed NCT00176904 Phase 2, Phase 3 Busulfan, Cyclophosphamide, Antithymocyte Globulin
5 L-DEP as an Initial Treatment for EBV-HLH Recruiting NCT02912702 Phase 3 Pegaspargase;doxorubicin hydrochloride liposome injection;etoposide;methylprednisolone;Etoposide;dexamethasone
6 Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology Recruiting NCT02862054 Phase 2, Phase 3
7 L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis Recruiting NCT02631109 Phase 3 Pegaspargase;doxorubicin;etoposide;methylprednisolone
8 A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis Recruiting NCT01818492 Phase 2, Phase 3
9 Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Recruiting NCT02004691 Phase 2, Phase 3 placebo (saline);GZ402665
10 Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004 Active, not recruiting NCT00426101 Phase 3 Dexamethasone;Etoposide;Cyclosporin
11 Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C Active, not recruiting NCT02612129 Phase 2, Phase 3 arimoclomol;Placebo
12 Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease Active, not recruiting NCT02534844 Phase 2, Phase 3 VTS-270;Sham Procedure Control
13 Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis Not yet recruiting NCT03312751 Phase 3 Emapalumab
14 Trial of DA-EPOCH Regimen for NHL With HLH Unknown status NCT01818908 Phase 2 DA-EPOCH
15 Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis Completed NCT01104025 Phase 2 ATG, rabbit;Etoposide;Methotrexate;hydrocortisone;Dexamethasone
16 Stem Cell Transplant for Immunologic or Histiocytic Disorders Completed NCT00176865 Phase 2 Fludarabine;Melphalan;Anti-thymocyte globulin (ATG);Campath 1H;Cyclosporin A;Mycophenolate mofetil;Intravenous immunoglobulin (IVIG)
17 Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 Completed NCT02124083 Phase 1, Phase 2 Vorinostat
18 Biomarker Validation for Niemann-Pick Disease, Type C: Safety and Efficacy of N-Acetyl Cysteine Completed NCT00975689 Phase 1, Phase 2 N-Acetyl Cysteine
19 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
20 Miglustat in Niemann-Pick Type C Disease Completed NCT00517153 Phase 2 miglustat
21 Treatment of Familiar Lymphohistiocytosis Recruiting NCT02472054 Phase 1, Phase 2 Alemtuzumab;Methyl Prednisolone (MP);Cyclosporin A (CSA)
22 Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Recruiting NCT02385110 Phase 2 Alemtuzumab;Etoposide;Dexamethasone;Methotrexate;Tocilizumab
23 Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Recruiting NCT02007239 Phase 2 tocilizumab
24 A Study of Lenalidomide for Adult Histiocyte Disorders Recruiting NCT02523040 Phase 2 Lenalidomide
25 Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Vemurafenib
26 A Study to Investigate the Safety and Efficacy of an Anti-IFN-gamma mAb in Children With Systemic Juvenile Idiopathic Arthritis (sJIA) Developing Macrophage Activation Syndrome/ Secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH) Recruiting NCT03311854 Phase 2 NI-0501
27 Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease Recruiting NCT03201627 Phase 1, Phase 2 Lithium Carbonate
28 Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1 Recruiting NCT02912793 Phase 1, Phase 2 Hydroxypropyl-beta-cyclodextrin
29 Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency Recruiting NCT02292654 Phase 1, Phase 2 Olipudase alfa
30 Immune Disorder HSCT Protocol Recruiting NCT01821781 Phase 2 Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
31 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts Recruiting NCT00368355 Phase 2 Ara-C;Cyclophosphamide
32 Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204) Active, not recruiting NCT01998633 Phase 2
33 Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders Active, not recruiting NCT01372228 Phase 1, Phase 2
34 A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency Enrolling by invitation NCT02004704 Phase 2 GZ402665
35 Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease Suspended NCT02281760 Phase 2 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
36 Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease Terminated NCT01727206 Phase 2 Tocilizumab
37 Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism Terminated NCT00668564 Phase 2 Cyclophosphamide;Campath-1H;Busulfan
38 Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease Completed NCT01747135 Phase 1 VTS-270
39 Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients Completed NCT01722526 Phase 1 Recombinant human acid sphingomyelinase
40 Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease Completed NCT00316498 Phase 1 OGT918
41 Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases Recruiting NCT02231710 Phase 1
42 Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1) Recruiting NCT02939547 Phase 1 Hydroxypropyl-beta-cyclodextrin
43 UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Recruiting NCT02254863 Phase 1
44 BMT Abatacept for Non-Malignant Diseases Recruiting NCT01917708 Phase 1 Abatacept
45 Human Placental-Derived Stem Cell Transplantation Recruiting NCT01586455 Phase 1 Human Placental Derived Stem Cell
46 Administration of Donor T Cells With the Caspase-9 Suicide Gene Active, not recruiting NCT01494103 Phase 1 AP1903
47 Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease) Terminated NCT00410566 Phase 1 rhASM;rhASM;rhASM;rhASM;rhASM
48 New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome Unknown status NCT01095146
49 Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders Unknown status NCT00006056 anti-thymocyte globulin;busulfan;cyclophosphamide;cyclosporine;etoposide;filgrastim;methotrexate
50 Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Unknown status NCT00005900

Search NIH Clinical Center for Non-Langerhans-Cell Histiocytosis

Cochrane evidence based reviews: histiocytosis, non-langerhans-cell

Genetic Tests for Non-Langerhans-Cell Histiocytosis

Anatomical Context for Non-Langerhans-Cell Histiocytosis

MalaCards organs/tissues related to Non-Langerhans-Cell Histiocytosis:

39
T Cells, Testes, Bone Marrow, Skin, Eye, Brain, Bone

Publications for Non-Langerhans-Cell Histiocytosis

Articles related to Non-Langerhans-Cell Histiocytosis:

(show all 25)
id Title Authors Year
1
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. ( 28679734 )
2017
2
Non-Langerhans cell histiocytosis. ( 26739442 )
2016
3
Spontaneous regression of infantile dural-based non-Langerhans cell histiocytosis after surgery: case report. ( 25634822 )
2015
4
Suprasellar non-Langerhans cell histiocytosis (Erdheim-Chester disease)--a case report. ( 23465991 )
2013
5
Retinal manifestations in a patient with xanthoma disseminatum (non-langerhans cell histiocytosis). ( 21484660 )
2011
6
Rare case of infratentorial non-Langerhans cell histiocytosis with lethal outcome presenting multiple diagnostic difficulties. ( 22025140 )
2011
7
Intracranial non-Langerhans cell histiocytosis presenting as an isolated intraparenchymal lesion. ( 20635081 )
2010
8
Endolymphatic non-langerhans cell histiocytosis of the larynx: report of an uncommon disease manifestation. ( 20463609 )
2010
9
Non-Langerhans cell histiocytosis with isolated CNS involvement: an unusual variant of Erdheim-Chester disease. ( 20337948 )
2010
10
Fibroblastic rheumatism: fibromatosis rather than non-Langerhans cell histiocytosis. ( 19615014 )
2010
11
Cerebral non-Langerhans cell histiocytosis in a 17-year-old patient with a headache: case report. ( 19363626 )
2009
12
Non-Langerhans cell histiocytosis in a child with Kawasaki disease. ( 21686403 )
2009
13
Diffuse xanthogranulomatous dermatitis and systemic Langerhans cell histiocytosis: A novel case that demonstrates bridging between non-Langerhans cell histiocytosis and Langerhans cell histiocytosis. ( 19022530 )
2009
14
Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. ( 16020507 )
2005
15
[Erdheim-Chester disease: a non-Langerhans cell histiocytosis. A clinical-case and review of the literature]. ( 15344569 )
2004
16
Primary cerebral non-Langerhans cell histiocytosis: MRI and differential diagnosis. ( 12221448 )
2002
17
A child with both Langerhans and non-Langerhans cell histiocytosis. ( 12383099 )
2002
18
Problems in differential diagnosis of non Langerhans cell histiocytosis with pituitary involvement: case report and review of literature. ( 12665654 )
2002
19
Progressive histiocytosis: description of a case of slow-course non-Langerhans cell histiocytosis. ( 12399681 )
2002
20
Benign cephalic histiocytosis progressing into juvenile xanthogranuloma: a non-Langerhans cell histiocytosis transforming under the influence of a virus? ( 10698221 )
2000
21
Non-Langerhans cell histiocytosis associated with lymphocyte-predominant Hodgkin's disease. ( 10564322 )
1999
22
Generalized non-Langerhans cell histiocytosis: four cases illustrate a spectrum of disease. ( 7737766 )
1995
23
A unique non-Langerhans cell histiocytosis with some features of generalized eruptive histiocytoma. ( 8034797 )
1994
24
An unusual case of non-Langerhans cell histiocytosis. ( 8294600 )
1994
25
Congenital self-healing non-Langerhans cell histiocytosis. ( 3058480 )
1988

Variations for Non-Langerhans-Cell Histiocytosis

Expression for Non-Langerhans-Cell Histiocytosis

Search GEO for disease gene expression data for Non-Langerhans-Cell Histiocytosis.

Pathways for Non-Langerhans-Cell Histiocytosis

Pathways related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.11 CD68 HEXA NPC1 NPC2 SMPD1
2 10.36 CD68 SMPD1
3
Show member pathways
10.1 NPC1 NPC2

GO Terms for Non-Langerhans-Cell Histiocytosis

Cellular components related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.7 CD163 F13A1 IL1RN NPC1 NPC2 SMPD1
2 lysosome GO:0005764 9.26 HEXA NPC1 NPC2 SMPD1
3 lysosomal lumen GO:0043202 8.8 HEXA NPC2 SMPD1

Biological processes related to Non-Langerhans-Cell Histiocytosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 response to cocaine GO:0042220 9.37 PITX3 SMPD1
2 muscle filament sliding GO:0030049 9.32 ACTC1 DES
3 low-density lipoprotein particle clearance GO:0034383 9.26 NPC1 NPC2
4 cholesterol transport GO:0030301 9.16 NPC1 NPC2
5 cholesterol efflux GO:0033344 8.96 NPC1 NPC2
6 response to drug GO:0042493 8.92 ACTC1 NPC1 SMPD1 SST

Sources for Non-Langerhans-Cell Histiocytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....